GlassScriptPhysician profile
Jasmine Severan
NPI 1225712367
$5,065.08
in general payments reported to CMS, 2019-2025
20 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.98 · 2024: $3,947 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219 · Travel and Lodging: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.52 |
| Travel and Lodging | $1,846.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,415.58 | 2024-2025 | Linq II, Symplicity G3, Azure Xt Dr Mri Surescan |
| Abiomed | $1,211.24 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $337.39 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.51 | 2024-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $240.95 | 2024-2025 | Assure Wcd |
| Penumbra, INC. | $140.03 | 2024 | Indigo System |
| Phathom Pharmaceuticals, INC. | $100.00 | 2024 | Voquezna |
| Abbott Laboratories | $86.65 | 2025 | Cardiomems, Assurity |
| Biosense Webster, INC. | $46.03 | 2025 | Na, Nuvision Ice Catheter |
| Scpharmaceuticals INC. | $33.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $28.04 | 2023-2024 | Farxiga |
| Terumo Medical Corporation | $27.90 | 2023-2024 | Metacross Otw, Glidewire, Angio-Seal |
| Ge Healthcare | $25.81 | 2024 | |
| Biogen, INC. | $21.48 | 2024 | Skyclarys |
| Merck Sharp & Dohme LLC | $18.41 | 2024 | Verquvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.97 | 2025 | |
| Amgen INC. | $15.70 | 2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $15.04 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $13.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Severan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.